A. Hoos

Societal preference values for advanced melanoma health states in the United Kingdom and Australia

A. Levy, P. Hersey, M. Middleton, 2009, British Journal of Cancer.

Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative

S. Skovlund, K. Deane, B. Nafria, 2019, BMJ Innovations.

Culture and Process Change as a Priority for Patient Engagement in Medicines Development

P. Robinson, Marc Boutin, J. Geissler, 2016, Therapeutic innovation & regulatory science.

Randomised trial of single and repeated fibrin glue compared with injection of polidocanol in treatment of bleeding peptic ulcer

P. Swain, P. Rutgeerts, J. Halttunen, 1997, The Lancet.

From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients

W Goettsch, D Samaha, S. Schneeweiss, 2015, Clinical pharmacology and therapeutics.

What do stakeholders expect from patient engagement: Are these expectations being met?

P. Robinson, Marc Boutin, J. Geissler, 2018, Health expectations : an international journal of public participation in health care and health policy.

Partnering With Patients in the Development and Lifecycle of Medicines

Marc Boutin, A. Joos, G. Tougas, 2015, Therapeutic innovation & regulatory science.

Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan

M. Pearson, H G Eichler, K A Oye, 2016, Clinical pharmacology and therapeutics.

Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation

G. Hirsch, S. Garner, Richard J. Bergstrom, 2016, Therapeutic innovation & regulatory science.